Enterokinase

Restriction protease From calf intestine Enteropeptidase, E.C. 3.4.21.9

Cat. No. 1 334 115 $3 \times 30 \ \mu g$ Cat. No. 1 351 311 $3 \times 250 \ \mu g$

Product description

Commercial availability

	Lyophilized.		
Specificity	Enterokinase is a serine protease that recognizes the amino acid sequence		
	-Asp-Asp-Asp-Asp-Lys-↓-X-		
	with a high specificity. The enterokinase activates its natural substrate trypsinogen and releases trypsin by cleavage at the C-terminal end of this sequence (1). The aspartic acid residues can be substituted by glutamic acid (2).		
Application			
	This recognition sequence, however, can also be used as a restriction cleavage site for processing recombinant proteins (3). For this purpose, the desired protein is fused at the C-terminal of the recognition sequence. After purification of the entire fusion protein, the protein or peptide is released by incubation with enterokinase. A constant quality is guaranteed by testing each lot with a recombinant fusion protein. The release of the desired protein or peptide component from a fusion protein is affected by the adjacent amino acid sequences at the cleavage site as well as by the size of the two fused components and by the accessibility of the cleavage site (2).		
Purity	The restriction protease enterokinase does not contain any further protein like bovine serum albumin as stabilizer. It is present in a highly purified form: Purity control by SDS polyacrylamide gel electrophoresis (SDS-PAGE) ensures a constant quality from lot to lot. The composition of the lyophilisate does not influence the cleavage of the fusion proteins.		
Note	The content of one vial may be used for several simultaneous digests. In order to repeat the digest a new vial should be taken. Thereby the utmost reproducibility can be guaranteed and contamination will be avoided.		
Stability	stable at 2-8° C, stored dry. A solution of enterokinase, stored at 2-8° C, can be used up to one week.		

Version 3, October 1999

Store at 2-8° C

Procedure

Enterokinase cleavage is carried out at an enzyme/substrate ratio (w/w) of 1/20-1/200 for 1-24 h. For each fusion protein pilot experiments should be done to find out suitable conditions. The optimal pH for the reaction is between 7.0-8.0, but the enzyme can be used within pH 6.0-8.5. Suitable buffers are, 50 mM Tris* or 50 mM Mes*. In phosphate buffer the activity is significantly reduced. Higher concentrations of salts, e.g. NaCl, inhibit the reaction. Addition of CaCl₂ to the incubation mixture does not increase the reaction rate (4). Unsoluble aggregates of fusion proteins are cleaved extremely slowly or not at all. Denaturing of the fusion protein might be necessary to increase the accessibility of the cleavage site. Suitable denaturing agents are listed in the table. On application of urea it is recommended to also add 20 mM methylamine. In order to achieve a suitable concentration of the denaturing agent in the reaction mixture, the protein has to be correspondingly diluted with incubation buffer.

- Adjust the concentration of the fusion protein to 0.3-1 mg/ml and a pH between 7.0-8.0. If the fusion protein is dissolved in phosphate buffer or in case of high ionic strength, it is necessary to exchange the incubation buffer either by dialysis or gelfiltration.
- Dissolve the content of a vial of enterokinase in redist. water to obtain a concentration of 0.25-0.3 mg/ml. If necessary, a further dilution should be done using the incubation buffer.
- 3. Pilot experiments:

Carry out the pilot experiments with a small portion of your fusion protein. Incubate 25 μ g fusion protein (25 μ l with 1mg/ml) with 0.6 μ g enterokinase (2 μ g with 0.3 mg/ml). Take 5 μ g samples of the reaction mixture after 1, 3, 6 and 24 h, add 5 μ l 2 × concentrated SDS-PAGE sample buffer, boil for 5 min and store at -15 to -25° C until SDS-PAGE is performed. To detect a possible unspecific cleavage either by autolysis or by proteolytic contaminations of the fusion protein a control incubation without enterokinase is recommended. To optimize the amount of enterokinase necessary for 100% cleavage do a similar experiment with variations of the enzyme concentration and 3 h incubation time.

Analyse the samples of an experiments, the corresponding control incubations and a sample of uncut fusion protein on a SDS-PAGE gel (5).



4. Incubate the main portion of the fusion protein using the optimized conditions deduced from the pilot experiments. Check for complete cleavage by SDS-PAGE and use as reference a sample of uncut fusion protein.



Fig.: Cleavage of a fusion protein with enterokinase Incubation was carried out in 50 mMTris buffer, pH 8.0, as described for the pilot experiments in the procedure. Lanes 1, 8: calibration proteins, combithek*; lane 2: uncut fusion protein; lanes 3, 4, 5, 6, 7: incubations of the fusion protein with enterokinase for 1, 3, 6, 20 and 32 h respectively.

Denaturant	Concentrations tested	Inhibition of cleavage
Urea (+ methylamine)	0.1 - 3 M	none
SDS*	0.01 - 1%	inhibitory at 0.01%
Hydrogenated Triton ¹⁾ X-100	0.01 - 1%	none
Tween ²⁾ 80*	0.01 - 1%	none
Acetonitrile	5%, 10%	none

Tab.: Influence of different denaturing agents on the cleavage rate of enterokinase.Incubation was carried out according to the procedure in 50 mMTris buffer, pH 8.0, for 1 h at 37°C; amount of enterokinase: 1/40 (w/w) of the fusion protein

References

- Keil, B. (1971) in The Enzymes, (Boyer, P. D., ed.) Vol. 3 pp. 249-275, Academic Press.
- 3
- Light, A. et al. (1980) *Analytical Biochemistry* **106**, 199-206. Hopp, T. P. et al. (1988) *Bio/Technology* **6**, 1204-1210. Fonseca, P. & Light, A. (1983) *J. Biol. Chem.* **258**, 14516-14520.
- Laemmli, U. K. (1970) Nature 227, 680-685.

available from Roche Molecular Biochemicals

Triton X-100 is a trademark of Rohm & Haas, Philadelphia/USA

2) Tween 80 is a trademark of ICI Americas Inc., Wilmington/USA

E-mail Address

argentina.biochem@roche.com Argentina biochem.au@roche.com Gerhard.Muehlbauer@roche.com biochem.be@roche.com Valent@mbox.cit.bg africhem@camnet.cm biochem.ca@roche.com biochem.cn@roche.com Info@medisell.com.cy Bm-comp@bm-comp.cz ou.melestrum@neti.ee pharsc.et@telecom.net.et biochem_fi@oriola.fi biochem fr@roche com biochemInfo.de@roche.com Bm_roche@hotmail.com h.hajian@tebtech.com tubanegin@istn.irost.com Dyn@netvision.net.il it.biochem@roche.com bmkkbio@cet.co.jp pharmakp@net2000ke.com Bmskorea@chollian.net react@ncc.moc.kw Raitis@invitros.lv Sakkijha@rdleb.com Gintaras@eksma.lt diagnostics@prophac.lu Vccl@vol.net.mt Aiouche.echo@dounia.net.ma biocheminfo.nl@roche.com biochem.nz@roche.com bofungwu@linkserve.com.ng biochem.se@roche.com biochem.pt@roche.com Topdiag@fx.ro biochem.sg@roche.com roche.diagnostics@siol.net south_africa.bioboffin@roche.com biochem.es@roche.com biochem.se@roche.com BiochemInfo.CH@roche.com Jean-Marie.kindbeiter@roche.com bmuae@emirates.net.ae uk.biochem@roche.com biochemts.us@roche.com Mvalentiner@telcel.net.ve dusica@eunet.yu biochemts.row@roche.com

Country

Australia Δustria Belgium Bulgaria Cameroon Canada China Cyprus Czech Republic Estonia Ethiopia Finland France Germany India Iran Iran Israel Italv Japan Kenya Korea Kuwait Latvia Lebanon I ithuania Luxembourg Malta Morocco Netherlands New Zealand Nigeria Norway Portugal Romania Singapore Slovenia South Africa Spain Sweden Switzerland Tunisia United Arab Emirates United Kingdom USA Venezuela Yugoslavia All other countries

http://biochem.roche.com/pack-insert/1334115a.pdf

Argentina 541 954 5555; Australia (02) 9899 7999; Austria (01) 277 87; Belgium (02) 247 (4930, Brazili +55 (1) 366 3365; Bulgaria +3529262408; Cameroon 237-370269; Canada (450) 086 7050; (800) 361 2070; Chile 00 56 (2) 22 33 737 (central) 00 56 (2) 22 32 099 (Exec); China 86 21 6427 5586; Colombia 0057-1-3412797; Cyprus +357-2-311362; Czech Republic (0324) 45 54, 58 71-2; Denmark +45 363 999 58; Egypt 20-2-3619047; Estonia 372-7-447600; Ethiopia 251-1-552799; Finland (09) 429 2342; France 04 76 76 30 87; Germany (0621) 759 S568; Greece 3 (01) 67 40 238; Hong Kong (852) 2485 7596; India +91-22-8379006; Indone-sia 62 (021) 252 3820 ext. 755; Iran +98-21-8072374 / +98-21-8797027; Israel 972-6- 6380569; Italy 039 247 4109-4181; Japan 03 3432 3155; Kenya +254-2-750112; Korea 82-2-3471-6500; Kuwait +965-4837859; Latvia 371-787828309; Lebano Fax: 0901-1-399667; Lithuania 370-2-729715; Luxembourg +352-496098; Malta Fax: +356-341087; Morocco Fax: +212-2 944040; Malaysia 60 (03) 755 5039; Mexico (5) 227 8967; Netherlands (036) 539 4911; New Zealand (09) 276 4157; Nigeria +234-1-521767; Norway (47) 23 373300; Philippines (632) 810 7246; Poland +48 (22) 22 66 84 305; Portugal (01) 4171717; Republic of Ireland 1 800 40 90 41; Romania +40-1-2123763; Russia (49) 621 759 8636 Fax: (49) 621 759 8611; Saudia Arabia +966-1-4010364; Singapore 0065 272 9200; Slovenia +386 61 1363528; South Africa (011) 886 2400; South Korea 02 569 6902; Spain (93) 201 4411; Sweden (08) 404 8800; Switzerland +41 (41) 799 6161; Taiwan (02) 736 7125; Thailand 66 (2) 274 07 08 (12 line); Turkey 0090 212 216 32 80; United Arab Emirates +971-4-694351; United Kingdom (0800) 521578; USA (800) 428 5433. Venezuela Fax: +0058-4810697; Yugoslavia +381 11 137163.



Roche Diagnostics GmbH Roche Molecular Biochemicals Sandhofer Strasse 116 D-68305 Mannheim Germany